These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 22591300

  • 1. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.
    Ropper AH.
    N Engl J Med; 2012 May 17; 366(20):1938-9. PubMed ID: 22591300
    [No Abstract] [Full Text] [Related]

  • 2. Natalizumab-associated progressive multifocal leukoencephalopathy.
    Cervera C.
    N Engl J Med; 2012 Aug 30; 367(9):871; author reply 872. PubMed ID: 22931328
    [No Abstract] [Full Text] [Related]

  • 3. Natalizumab-associated progressive multifocal leukoencephalopathy.
    Mancini N, Clementi M, Burioni R.
    N Engl J Med; 2012 Aug 30; 367(9):871-2; author reply 872. PubMed ID: 22931329
    [No Abstract] [Full Text] [Related]

  • 4. [Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology].
    Warnke C, Adams O, Hartung HP, Gold R, Hemmer B, Hohlfeld R, Stangel M, Zipp F, Wiendl H, Kieseier BC.
    Nervenarzt; 2011 Oct 30; 82(10):1314-9. PubMed ID: 21656322
    [No Abstract] [Full Text] [Related]

  • 5. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 6. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 17; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 7. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
    Pitarokoili K, Gold R.
    Nat Rev Neurol; 2017 Dec 17; 13(12):710-712. PubMed ID: 29146954
    [No Abstract] [Full Text] [Related]

  • 8. Natalizumab risk stratification: role of a two- step anti-JCV antibody assay.
    O'Connor PW.
    Can J Neurol Sci; 2012 Sep 17; 39(5):670-5. PubMed ID: 22931715
    [No Abstract] [Full Text] [Related]

  • 9. Comment on 'Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?' Maillart et al.
    Tur C, Montalban X.
    Mult Scler; 2014 Apr 17; 20(4):510-1. PubMed ID: 24468818
    [No Abstract] [Full Text] [Related]

  • 10. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Apr 17; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 11. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
    Tur C, Tintoré M, Vidal-Jordana A, Castilló J, Galán I, Río J, Arrambide G, Comabella M, Arévalo MJ, Horno R, Vicente MJ, Caminero A, Nos C, Sastre-Garriga J, Montalban X.
    Mult Scler; 2012 Aug 17; 18(8):1193-6. PubMed ID: 22383232
    [Abstract] [Full Text] [Related]

  • 12. Anti-JC Virus Antibodies in a Large German Natalizumab-Treated MS Cohort.
    Zahednasab H.
    Neurology; 2012 Nov 06; 79(19):2010; author reply 2010-1. PubMed ID: 23128444
    [No Abstract] [Full Text] [Related]

  • 13. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Peaureaux D, Pignolet B, Biotti D, Bucciarelli F, Gaina J, Bucur C, Clanet M, Martin-Blondel G, Brassat D.
    Mult Scler; 2015 Apr 06; 21(5):671-2. PubMed ID: 25305251
    [No Abstract] [Full Text] [Related]

  • 14. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.
    Mult Scler; 2015 Oct 06; 21(12):1600-3. PubMed ID: 25662344
    [Abstract] [Full Text] [Related]

  • 15. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
    Damasceno A, von Glehn F, Martinez AR, Longhini AL, Deus-Silva L, Brandão CO, Santos LM, Damasceno BP.
    Mult Scler; 2011 Nov 06; 17(11):1397-8. PubMed ID: 21900356
    [No Abstract] [Full Text] [Related]

  • 16. Fatal natalizumab-associated progressive multifocal leukoencephalopathy with initial low JCV antibody index in a multiple sclerosis patient.
    Hay M, Leguy S, Cahagne V, Lassalle N, Le Page E, Michel L.
    Rev Neurol (Paris); 2024 Jun 06; 180(6):565-567. PubMed ID: 38429158
    [No Abstract] [Full Text] [Related]

  • 17. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, Stein MC, Viscidi RP, Ngo LH, Koralnik IJ.
    N Engl J Med; 2009 Sep 10; 361(11):1067-74. PubMed ID: 19741227
    [Abstract] [Full Text] [Related]

  • 18. JCV-negative natalizumab-associated progressive multifocal leukoencephalopathy: a clinico-radiological diagnosis.
    Travasarou M, Marousi S, Papageorgiou E, Karageorgiou CE.
    Clin Neurol Neurosurg; 2013 Jun 10; 115(6):827-9. PubMed ID: 22920632
    [No Abstract] [Full Text] [Related]

  • 19. Natalizumab and fingolimod: insight into their relative efficacies in clinical practice.
    Conway DS, Cohen JA.
    Mult Scler; 2014 Sep 10; 20(10):1280-1. PubMed ID: 25160120
    [No Abstract] [Full Text] [Related]

  • 20. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun 10; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.